Lymphoma Experience took a great step by incentivizing us to discuss what the standards in Latin America should be. It is amazing to witness the efforts of colleagues across the world in bringing the best care to patients. Congrats on an amazing conference! Joaquín Díaz-Schmidt Daniel Ernst

Nuevamente fue una gran experiencia! Gracias, nos vemos en #LEx26 !

Muchas gracias!

Join us next week for the kickoff of our 14th webinar series "Demystifying Pharma"!

Great experience: Excelent lectures and case discussions with outsatnding people in abeautiful Rio de Janeiro.

podcasts.apple.com/cl/podcast/fas…

Sharing ideas to acheive international colaboración in linfomas. The aim is to develop relevant information to try to improve the prognosis of our patients. Thank you @massimofederico ⁦Stefano Luminari, MD⁩ ⁦Andrés Ferreri⁩ @mariagomesdasouza

This is a crucial issue that requires attention. Waiting an entire year for a response should not be acceptable, but unfortunately, it happens too often. In Latin America, only 14% of cancer research papers are published the same year they are completed. It is necessary to

Big things are happening in Buenos Aires this week! 🧬 GATMO 2025 is just around the corner! 📅 May 23–24 | 📍CABA We can’t wait to welcome you! (🥳) Let’s talk science, share ideas & have some fun! ✨ See you there! #GATMO2025 #NextGenHematology #Networking

Challenges in managing and reporting adverse events in haematological malignancies in low-income and middle-income countries - The Lancet Haematology thelancet.com/journals/lanha…

Here we reviewed molecular advances in MDS with a Latin American Perspective mdpi.com/3340472 #mdpigenes vía Genes MDPI

CONGRESS | #EHA2025 | POSTER Astrid Pavlovsky presented long-term findings from the GATLA LH-05 trial evaluating PET-CT-adapted treatment following 3 cycles of ABVD in patients with classical Hodgkin #lymphoma (N = 557). PET3-negative patients had significantly better PFS at 60

Save the date! Our next webinar series will run throughout July - stay tuned for updates

Impressive response rates with #epcoritamab + R-ICE IN R/R DLBCL with ORR 87% and CR rate of 65%. Also in patients with early relapses within 12m 1L therapy #hematology #lymphoma #lymsm

Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025

Check out our 2 posters: Long term follow up of Pet adapted therapy in all stages of HL and RWE of use of consolidation of BV post auto. ⁦Lorena Fiad⁩. Nice visita from ⁦Carlos Chiattone⁩ and ⁦Eva Domingo-Domenech⁩ ⁦International Conference on Malignant Lymphoma⁩ #ICML2025

Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At International Conference on Malignant Lymphoma, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy

Felicitaciones por la excelente “Noche”!! Muchas gracias Beone y Astrid Pavlovsky por la invitación!

My honor to participate with Dr Andrew Davies in this high quality academic activity organized by Dr Agarwal for the Mumbai Hematologic Group

The SUNMO trial manuscript is now published at Journal of Clinical Oncology! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm L. Elizabeth Budde, M.D., Ph.D. ascopubs.org/doi/10.1200/JC…